Table 3 Treatment-related adverse events.

From: Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer

 

No. (%)

All Grade

Grade 3 or 4

Grade 1

Grade 2

Grade 3

Grade 4

Elevated AST

34 (74.0)

8 (17.4)

10 (21.7)

16 (34.8)

8 (17.4)

0

Elevated ALT

30 (65.2)

8 (17.4)

5 (10.9)

17 (37.0)

8 (17.4)

0

Leukopenia

30 (65.2)

6 (13.0)

6 (13.0)

18 (39.1)

4 (8.7)

2 (4.3)

Hand-foot syndrome

25 (54.3)

3 (6.5)

14 (30.4)

8 (17.4)

3 (6.5)

0

Neutropenia

24 (52.2)

14 (30.4)

4 (8.9)

6 (13.0)

9 (19.6)

5 (10.9)

Alopecia

19 (41.3)

0

10 (21.7)

9 (19.6)

0

0

Fatigue

18 (39.1)

0

10 (21.7)

8 (17.4)

0

0

Thrombocytopenia

16 (34.8)

9 (19.6)

3 (6.5)

4 (8.7)

7 (15.2)

2 (4.3)

Rash

16 (34.8)

2 (4.3)

4 (8.7)

10 (21.7)

2 (4.3)

0

Canker sore

11 (23.9)

0

5 (10.9)

6 (13.0)

0

0

Anorexia

10 (21.7)

0

5 (10.9)

5 (10.9)

0

0

Gingivitis

8 (17.4)

0

7 (15.2)

1 (2.2)

0

0

Lose weight

8 (17.4)

0

6 (13.0)

2 (4.3)

0

0

Pneumonia

8 (17.4)

1 (2.2)

1 (2.2)

6 (13.0)

1 (2.2)

0

Voice hoarse

8 (17.4)

0

8 (17.4)

0

0

0

Diarrhea

7 (15.2)

0

5 (10.9)

2 (4.3)

0

0

Hypertension

7 (15.2)

0

2 (4.3)

5 (10.9)

0

0

Hypothyroidism

7 (15.2)

1 (2.2)

3 (6.5)

3 (6.5)

1 (2.2)

0

Proteinuria

7 (15.2)

0

5 (10.9)

2 (4.3)

0

0

Capillary hemangioma

7 (15.2)

0

6 (13.0)

1 (2.2)

0

0

Insomnia

6 (13.0)

0

2 (4.3)

4 (8.7)

0

0

Fever

6 (13.0)

1 (2.2)

3 (6.5)

2 (4.3)

1 (2.2)

0

Elevated bilirubin

6 (13.0)

3 (6.5)

1 (2.2)

2 (4.3)

3 (6.5)

0

Pain

6 (13.0)

1 (2.2)

0

5 (10.9)

1 (2.2)

0

Elevated CK-MB

5 (10.9)

0

4 (8.7)

1 (2.2)

0

0

Hypoalbuminema

5 (10.9)

0

1 (2.2)

4 (8.7)

0

0

Hemoglobin reduction

5 (10.9)

2 (4.3)

2 (4.3)

1 (2.2)

2 (4.3)

0

Constipation

4 (8.7)

0

3 (6.5)

1 (2.2)

0

0

Hemoglobinuria

4 (8.7)

0

4 (8.7)

0

0

0

Headache

4 (8.7)

0

3 (6.5)

1 (2.2)

0

0

Hydropericardium

3 (6.5)

1 (2.2)

2 (4.3)

0

1 (2.2)

0

Infusion reaction

3 (6.5)

0

0

3 (6.5)

0

0

Stomachache

3 (6.5)

0

2 (4.3)

1 (2.2)

0

0

Hyperthyroidism

2 (4.3)

0

0

2 (4.3)

0

0

Blurred vision

2 (4.3)

0

1 (2.2)

1 (2.2)

0

0

  1. AST aspartate aminotransferase, ALT alanine transaminase, CK-MB creatine phosphokinase-MB.